Literature DB >> 25707420

Sweet syndrome as terminal event in ruxolitinib-treated myelofibrosis.

Basabi Chatterjee1, Usama Rqieh, Paul Greaves, Daniela Piras, John Firth, Khalid Saja.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25707420     DOI： 10.1111/bjh.13334

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  3 in total

1.  Necrotizing neutrophilic dermatosis: A diagnostic challenge with a need for multi-disciplinary recognition, a case report.

Authors:  Asha Gowda; Luisa Christensen; Samantha Polly; Danny Barlev
Journal:  Ann Med Surg (Lond)       Date:  2020-07-26

2.  Recurrent Subcutaneous Sweet's Disease in a Myelofibrosis Patient Treated with Ruxolitinib before Allogeneic Stem Cell Transplantation.

Authors:  Teppei Sakoda; Yoko Kanamitsu; Yasuo Mori; Kensuke Sasaki; Etsuko Yonemitsu; Konosuke Nagae; Goichi Yoshimoto; Kenjiro Kamezaki; Koji Kato; Katsuto Takenaka; Toshihiro Miyamoto; Masutaka Furue; Hiromi Iwasaki; Koichi Akashi
Journal:  Intern Med       Date:  2017-08-21       Impact factor: 1.271

Review 3.  Insights Into the Pathogenesis of Sweet's Syndrome.

Authors:  Michael S Heath; Alex G Ortega-Loayza
Journal:  Front Immunol       Date:  2019-03-12       Impact factor: 7.561
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.